The future of insulin therapy for patients with type 2 diabetes mellitus

Journal of the American Osteopathic Association

Volumn 113, Issue 4 SUPPL.2, 2013, Pages

  Tibald, Joseph M ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DELAYED RELEASE FORMULATION; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INCRETIN; INSULIN;

ANALYSIS; DELAYED RELEASE FORMULATION; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; HUMAN; PHYSIOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

BLOOD GLUCOSE; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN;

EID: 84876401865     PISSN: 00986151     EISSN: 19451997     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Best JD, Drury PL, Davis TM, et al. Glycemic control over 5 years in 4,900 people with type 2 diabetes: real-world diabetes therapy in a clinical trial cohort. Diabetes Care. 2012;35(5):1165-1170.
2. Tibaldi JM. Evolution of insulin development: focus on key parameters. Adv Ther. 2012;29(7):590-619.
3. Defronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus [Banting Lecture]. Diabetes. 2009;58(4):773-795.
4. LeRoith D. Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. Am J Med. 2002;113(suppl 6A):3S-11S.
5. Fanelli CG, Porcellati F, Rossetti P, Bolli GB. Glucagon: the effects of its excess and deficiency on insulin action. Nutr Metab Cardiovasc Dis. 2006;16(suppl 1):S28-S34.
6. Kawahito S, Kitahata H, Oshita S. Problems associated with glucose toxicity: role of hyperglycemia-induced oxidative stress. World J Gastroenterol. 2009;15(33):4137-4142.
7. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153-165.
8. Holst JJ, Deacon CF, Vilsbøll T, Krarup T, Madsbad S. Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends Mol Med. 2008;14(4):161-168.
9. Drucker DJ. Enhancing the action of incretin hormones: a new whey forward? Endocrinology. 2006;147(7):3171-3172.
10. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care. 2012;35(suppl 1):S11-S63.
11. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach-Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379.
12. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540-559.
13. Rolla AR. What about insulin as an immediate first step for type 2 diabetes? Diabetes Obes Metab. 2009;11(suppl 5):19-22.
14. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care. 2004;27(5):1028-1032.
15. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008;371(9626):1753-1760.
16. Hu Y, Li L, Xu Y, et al. Short-term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and β-cell function in subjects with long-term remission. Diabetes Care. 2011;34(8):1848-1853.
17. Bhattacharya S, Ammini AC, Jyotsna V, Gupta N, Dwivedi S. Recovery of β-cell functions with low-dose insulin therapy: study in newly diagnosed type 2 diabetes mellitus patients. Diabetes Technol Ther. 2011;13(4):461-465.
18. Harrison LB, Adams-Huet B, Raskin P, Lingvay I. β-cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care. 2012;35(7):1406-1412.
19. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care. 2003;26(3):881-885.
20. Hirsch IB. Intensifying insulin therapy in patients with type 2 diabetes mellitus. Am J Med. 2005;118(suppl 5A):21S-26S.
21. Jang HC, Guler S, Shestakova M; for the PRESENT Study Group. When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? results from a subanalysis of the PRESENT study. Int J Clin Pract. 2008;62(7):1013-1018.
22. Meneghini L, Mersebach H, Kumar S, Svendsen AL, Hermansen K. Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study. Endocr Pract. 2011;17(5):727-736.
23. Holman RR, Farmer AJ, Davies MJ, et al; for the 4-T Study Group. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361(18):1736-1747.
24. Pratley RE, Nauck M, Bailey T, et al; for the 1860-LIRA-DDP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375(9724):1447-1456.
25. Pratley RE, Nauck MA, Bailey T, et al. Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care. 2012;35(10):1986-1993.
26. Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376(9739):431-439.
27. Russell-Jones D, Cuddihy RM, Hanefeld M, et al; DURATION-4 Study Group. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week doubleblind study. Diabetes Care. 2012;35(2):252-258.
28. Hong ES, Khang AR, Yoon JW, et al. Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. Diabetes Obes Metab. 2012;14(9):795-802.
29. Vilsboll T, Rosenstock J, Yki-Jarvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(2):167-177.
30. Levin P, Wei W, Wang L, Pan C, Douglas D, Baser O. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes. Curr Med Res Opin. 2012;28(3):439-446.
31. Lind M, Jendle J, Torffvit O, Lager I. Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Prim Care Diabetes. 2012;6(1):41-46.
32. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulintreated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011;154(2):103-112.
33. Arnolds S, Dellweg S, Clair J, et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care. 2010;33(7):1509-1515.
34. Thong KY, Jose B, Sukumar N, et al. Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit. Diabetes Obes Metab. 2011;13(8):703-710.
35. Barnett AH, Charbonnel B, Donovan M, Fleming D, Chen R. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin. 2012;28(4):513-523.
36. DeVries JH, Bain SC, Rodbard HW, et al; for the Liraglutide Detemir Study Group. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care. 2012;35(7):1446-1454.
37. DeFronzo RA. Overview of newer agents: where treatment is going. Am J Med. 2010;123(3 suppl):S38-S48.
38. Nasrallah SN, Reynolds LR. Insulin degludec, the new generation basal insulin or just another basal insulin? Clin Med Insights Endocrinol Diabetes. 2012;5:31-37.
39. Moser EG, Morris AA, Garg SK. Emerging diabetes therapies and technologies. Diabetes Res Clin Pract. 2012;97(1):16-26.
40. Owens DR. Insulin preparations with prolonged effect. Diabetes Technol Ther. 2011;13(suppl 1):S5-S14.
41. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14(9):859-864.
42. Zinman B, Fulcher G, Rao PV, et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet. 2011;377(9769):924-931.
43. Birkeland KI, Home PD, Wendisch U, et al. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care. 2011;34(3):661-665.
44. Garber AJ, King AB, Del Prato S, et al; for the NN1250-3582 (BEGIN BB T2D) Trial Investigators. Insulin degludec, an ultralongacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1498-1507.
45. Heise T, Tack CJ, Cuddihy R, et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabetes Care. 2011;34(3):669-674.
46. Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultra-longacing basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1489-1497.
47. Home PD, Meneghini L, Wendisch U, et al. Improved health status with insulin degludec compared with insulin glargine in people with type 1 diabetes. Diabet Med. 2012;29(6):716-720.
48. Heise T, Nosek L, Bottcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14(10):944-950.
49. Meneghini L. Flexible once-daily dosing of insulin degludec does not compromise glycemic control or safety compared to insulin glargine compared to insulin glargine given once daily at the same time each day in people with type 2 diabetes. In: Program and Abstracts of the American Diabetes Association 71st Scientific Sessions, June 24-28, 2011. San Diego, CA. Abstract 35-LB.
50. Zinman B, Philis-Tsimikas A, Cariou B, et al; for the NN1250-3579 (BEGIN Once Long) Trial Investigators. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012;35(12):2464-2471.
51. Keegan A. Exit Exubera: inhalable insulin is withdrawn due to weak sales. Diabetes Forecast. 2007;60(13):19.
52. Harper NJ, Gray S, De Groot J, et al. The design and performance of the Exubera pulmonary insulin delivery system. Diabetes Technol Ther. 2007;9(suppl 1):S16-S27.
53. Moses RG, Bartley P, Lunt H, et al. Safety and efficacy of inhaled insulin (AERx iDMS) compared with subcutaneous insulin therapy in patients with type 1 diabetes: 1-year data from a randomized, parallel group trial. Diabet Med. 2009;26(3):260-267.
54. Rave K, Heise T, Heinemann L, Boss AH. Inhaled technosphere insulin in comparison to subcutaneous regular human insulin: time action profile and variability in subjects with type 2 diabetes. J Diabetes Sci Technol. 2008;2(2):205-212.
55. Rave K, Heise T, Pfutzner A, Boss AH. Coverage of postprandial blood glucoseexcursions with inhaled technosphere insulin in comparison to subcutaneously injected regular human insulin in subjects with type 2 diabetes. Diabetes Care. 2007;30(9):2307-2308.
56. Rosenstock J, Bergenstal RM, Blevins TC, et al. title typecontributorBetter glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study/title [published online ahead of print November 27, 2012]. Diabetes Care. 2013;36(3):522-528.
57. Bergenstal RM, Rosenstock J, Arakaki RF, et al. A randomized, controlled study of once daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care. 2012;35(11):2140-2147.
58. Niskanen L, Leiter LA, Franek E, et al. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial. Eur J Endocrinol. 2012;167(2):287-294.